Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Carboplatin + Paclitaxel + Pembrolizumab & Non-Small-Cell-Lung-Cancer (NSCLC) (Squamous Cell Carcinoma), there is an explicit FDA and EMA approval for Carboplatin + Paclitaxel + Pembrolizumab as first-line treatment of metastatic Non-Small-Cell-Lung-Cancer (NSCLC) (Squamous Cell Carcinoma) (1, 2).
The randomized clinical phase III trial, identified as NCT02775435 (KEYNOTE-407), demonstrated that for patients with previously untreated metastatic Non-Small-Cell Lung Cancer (NSCLC) of the Squamous Cell Carcinoma type, the combination of Carboplati…